BOTANIX PHARMACEUTICALS LIMITED A recent analyst report by Euroz Hartleys predicting significant upside for Botanix if the Company's Sofpironium Bromide New Drug Application (NDA) is successful, has been featured on Stockhead.
Journalist Eddy Sunarto highlighted the analyst's prediction that the share price could triple if FDA approval for the treatment of primary axillary hyperhidrosis is achieved in Q3 of this year.
Read the full article.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Botanix Pharmaceuticals Ltd. published this content on 14 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 February 2023 22:12:32 UTC.
